GLUCOTRACK SELECTS CIRTEC MEDICAL AS MANUFACTURER FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITORGlobeNewsWire • 02/27/24
GLUCOTRACK ANNOUNCES THE APPOINTMENT OF LUIS MALAVÉ TO CHAIR OF THE BOARD OF DIRECTORSGlobeNewsWire • 02/13/24
GLUCOTRACK ANNOUNCES EARLY ACCURACY DATA FOR ITS IMPLANTABLE CONTINUOUS GLUCOSE MONITORGlobeNewsWire • 01/02/24
GLUCOTRACK ANNOUNCES 180-DAY EXTENSION TO REGAIN COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENTGlobeNewsWire • 11/30/23
GLUCOTRACK ANNOUNCES PRECLINICAL TESTING WITH IMPLANTABLE CONTINUOUS GLUCOSE MONITORGlobeNewsWire • 10/12/23
GLUCOTRACK ANNOUNCES POSITIVE DATA FROM FEASIBILITY STUDY FOR IMPLANTABLE CONTINUOUS GLUCOSE MONITORGlobeNewsWire • 07/25/23
Aegis Capital Corp. Acted as Sole Bookrunner on a $10 Million Underwritten Public Offering for GlucoTrack, Inc. (NASDAQ: GCTK)Accesswire • 04/17/23
GlucoTrack Announces Pricing of $10 Million Underwritten Public Offering of Common StockGlobeNewsWire • 04/13/23
GLUCOTRACK TO BEGIN RESEARCH & DEVELOPMENT OF NOVEL CONTINUOUS GLUCOSE MONITORING SYSTEMGlobeNewsWire • 10/10/22
GlucoTrack, Inc. Provides Development Update on its Gen 2 Non-Invasive Glucose MonitorGlobeNewsWire • 06/22/22
GlucoTrack, Inc. Announces Effectiveness of Corporate Name Change and Ticker Symbol ChangeGlobeNewsWire • 03/14/22